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Botulinum neurotoxins (BoNTs) can cause paralysis
at exceptionally low concentrations and include
seven serotypes (BoNT/A-G). The chimeric BoNT/
DC toxin has a receptor binding domain similar to
the same region in BoNT/C. However, BoNT/DC
does not share protein receptor with BoNT/C.
Instead, it shares synaptotagmin (Syt) I and II as
receptors with BoNT/B, despite their low sequence
similarity. Here, we present the crystal structures of
the binding domain of BoNT/DC in complex with
the recognition domains of its protein receptors,
Syt-I and Syt-II. The structures reveal that BoNT/DC
possesses a Syt binding site, distinct from the estab-
lished Syt-II binding site in BoNT/B. Structure-based
mutagenesis further shows that hydrophobic inter-
actions play a key role in Syt binding. The structures
suggest that the BoNT/DC ganglioside binding sites
are independent of the protein receptor binding
site. Our results reveal the remarkable versatility in
the receptor recognition of the BoNTs.
INTRODUCTION
Botulinum neurotoxins (BoNTs) are a family of bacterial toxins.
They target neurons and block synaptic vesicle exocytosis at
nerve terminals, thereby causing paralysis and death in humans
and animals (Montal, 2010; Schiavo et al., 2000; Swaminathan,
2011). These toxins are the most potent toxins known and are
classified as one of the six most dangerous potential bioterror-
ism agents (Arnon et al., 2001; Gill, 1982). Due to their ability to
block overactive neurons and relax muscles, BoNTs are also
widely utilized to treat many human diseases, as well as for
cosmetic purposes (Dolly et al., 2009; Johnson, 1999).
Seven distinct BoNT serotypes exist (denominated as BoNT/
A-G; Montal, 2010; Schiavo et al., 2000; Swaminathan, 2011).
These toxins share the same overall structure and mode of
actions, but differ significantly on both protein sequences and
receptors/substrates. BoNTs are composed of a proteolytically
active light chain (50 kDa) and a heavy chain (100 kDa), con-
nected via a disulfide bond. The heavy chain contains two func-1602 Structure 21, 1602–1611, September 3, 2013 ª2013 Elsevier Lttional domains, a membrane translocation domain at the N-ter-
minal half (HN, 50 kDa) and a receptor binding domain at the
C-terminal half (HC, 50 kDa). The HC is composed of two sub-
domains, the N-terminal HCN domain, and the C-terminal HCC
domain. HCN is fairly conserved across BoNTs and may facilitate
the attachment of toxins to plasma membranes by binding to
phosphatidylinositol phosphates (Muraro et al., 2009; Zhang
and Varnum, 2012). HCC is one of the most diverse parts among
BoNTs and contains the receptor binding sites. BoNTs target
and enter neurons via receptor-mediated endocytosis. Once
inside neurons, the HN domain facilitates the translocation and
release of the toxin light chain into the cytosol, where they cleave
neuronal proteins required for synaptic vesicle exocytosis.
The guidingmodel for BoNT receptor recognition has been the
‘‘double-receptor’’ model proposed by Montecucco in 1986,
which states that BoNTs recognize neurons by binding to both
gangliosides as well as specific protein receptors (Montecucco,
1986). Gangliosides are complex glycolipids that have been
demonstrated to be an essential coreceptor for all seven BoNTs.
A conserved ganglioside binding site (GBS) with a SXWY motif
has been identified in BoNT/A, B, E, F, G, as well as the related
tetanus neurotoxin (Fotinou et al., 2001; Fu et al., 2009; Rummel
et al., 2004b, 2009; Schmitt et al., 2010; Stenmark et al., 2010,
2008; Swaminathan and Eswaramoorthy, 2000). Crystal struc-
tures of BoNT/A and BoNT/F with bound complex gangliosides
(GT1b and GD1a, respectively), as well as of BoNT/B bound
to sialyllactose, have provided further structural evidence to
establish this conserved GBS at the C terminus of HCC domain
(Benson et al., 2011; Stenmark et al., 2008; Swaminathan and
Eswaramoorthy, 2000).
Ganglioside binding in BoNT/C and D is more complicated.
They lack the conserved GBS, but analogous sites at the same
area of the proteins have been shown to bind gangliosides (Kar-
alewitz et al., 2012; Strotmeier et al., 2010, 2011; Zhang et al.,
2010), suggesting a distinct binding model. Furthermore, both
BoNT/C and D contain a solvent exposed hydrophobic loop, in
contrast to other serotypes. Mutations in this loop clearly disrupt
binding of gangliosides, suggesting that it is involved in binding
gangliosides (Karalewitz et al., 2010; Kroken et al., 2011b; Strot-
meier et al., 2010, 2011). Therefore, this loop has been termed as
the ganglioside binding loop (GBL, also known as WY loop),
although how the GBLmediates ganglioside binding still remains
unknown. In addition, a recent structure of BoNT/C has also re-
vealed a binding site for sialic acid, termed as Sia-1 site, which is
located at a different region from GBS in HCC (Strotmeier et al.,d All rights reserved
Table 1. Data Collection and Refinement Statistics
Data Collection BoNT/DC , Syt-I BoNT/DC , Syt-II
Space group P21 P21
Cell dimensions
a, b, c (A˚) 164.2, 57.6, 165.3 165.2, 57.8, 169.5
a, b, g () 90, 118.1, 90 90.0, 118.5, 90.0
Resolution (A˚) 48.5–2.65 (2.79–2.65) 48.3–2.6 (2.69–2.6)
Rsym (%) 12.5 (65.8) 11.3 (63.1)
I/s (I) 9.3 (2.3) 12.2 (2.3)
Completeness (%) 100 (100) 99.5 (98.5)
Redundancy 3.6 (3.6) 3.9 (3.9)
Refinement
Resolution 48.6–2.65 47.7–2.6
No. unique reflections 76,148 (12,157) 88,524 (14,062)
Rwork/Rfree 20.5/22.2 22.0/23.5
No. of atoms
Protein 10,175 10,146
Ligand 384 414
Water 260 430
B-factors
Protein 46.4 40.9
Ligand 59.8 49.2
Water 32 31.8
Rmsds
Bond lengths (A˚) 0.004 0.005
Bond angles () 0.79 0.89
Ramachandran plot (%)
Most favorable region 95.7 94.8
Additional allowed region 4.2 5.2
Outliers 0.1 0
Values in parentheses are for the highest-resolution shell.
Structure
BoNT/DC in Complex with Syt-I and Syt-II2011). Mutations within the Sia-1 site reduce ganglioside bind-
ing, demonstrating that it is a potential ganglioside binding
site. It is possible that the sialic acid binding pocket and the
GBL are different parts of the same ganglioside interaction area.
Recent studies have also identified that BoNT/B and G utilize
synaptic vesicle protein synaptotagmin (Syt, including two iso-
forms Syt-I and Syt-II) as their protein receptors (Chai et al.,
2006; Dong et al., 2003; Jin et al., 2006; Nishiki et al., 1993,
1994, 1996; Rummel et al., 2004a), whereas BoNT/A, D and E
use another vesicle protein, SV2, as receptor (Dong et al.,
2008, 2006; Mahrhold et al., 2006; Peng et al., 2011). In addition,
BoNT/F may also use SV2 as its receptor (Fu et al., 2009; Rum-
mel et al., 2009), although it has not been confirmed at the func-
tional level (Peng et al., 2011; Yeh et al., 2010). Among these
toxins, the crystal structure of BoNT/B bound to its receptor
Syt-II has been solved (Chai et al., 2006; Jin et al., 2006).
BoNT/G shares the highest sequence identity within the HCC
domain with BoNT/B among the seven BoNTs, and this Syt-II
binding site is also conserved in BoNT/G (Schmitt et al., 2010;
Stenmark et al., 2010). HowBoNT/A, D, E, and F bind SV2 still re-
mains to be determined at the structural level. It has also been
suggested that BoNT/Cmay not need a protein receptor (Tsuka-
moto et al., 2005). Instead, it may bind neurons via multiple gan-
gliosides (Karalewitz et al., 2010, 2012; Strotmeier et al., 2011).
In addition to the seven major serotypes, recent studies have
revealed a growing number of subtypes and mosaic toxins with
significant sequence differences from their parental serotypes
(Hill et al., 2007; Jacobson et al., 2008; Moriishi et al., 1996;
Smith et al., 2005; Zhang et al., 2011). In particular, we focused
on a mosaic toxin known as BoNT/DC (also known as BoNT/D
South Africa) (Moriishi et al., 1996). Its light chain and HN shares
high sequence identity with BoNT/D, but its HC is similar to
BoNT/C-HC. However, we previously reported that BoNT/DC
requires Syt-I/II as its protein receptor and identified the approx-
imate receptor interaction area (Peng et al., 2012). This is a case
of a mosaic toxin that uses a different receptor than its parental
toxin. Furthermore, the established Syt-II binding site found in
BoNT/B and G is not conserved in the apo structure of BoNT/
DC-HC, raising the question how BoNT/DC diverges from
BoNT/C and achieves the recognition of Syt-II. To understand
the molecular mechanism underlying these divergence/conver-
gence changes on receptor recognition in the BoNT family, we
solved the crystal structure of BoNT/DC-HC in complex with
the Syt-I and Syt-II recognition domains to 2.65 and 2.6 A˚,
respectively. The structures reveal that BoNT/DC possesses a
protein receptor binding site, distinct from the established Syt-
II binding site in BoNT/B. Mutational analysis verifies and high-
lights the importance of hydrophobic interactions in the receptor
binding. The structures suggest that the BoNT/DC ganglioside
binding sites are independent of the protein receptor binding
site and that BoNT/DC could bind three receptors on the
neuronal membrane.
RESULTS
Structure Determination of BoNT/DC-HC in Complex
with Synaptotagmin
Cocrystallization studies of BoNT/DC with Syt-I and Syt-II were
initiated using purified recombinant His6-tagged BoNT/DC-HCStructure 21, 1602–16and a synthesized peptide bearing the toxin binding site of
human Syt-I and rat Syt-II (residues 33–53 and 40–60, respec-
tively). This part of the receptor has been shown to be disordered
in solution and to contain the toxin binding region (Chai et al.,
2006; Jin et al., 2006; Peng et al., 2012). The crystals grew in
space group P21 and diffracted to 2.65 and 2.6 A˚ resolution,
respectively (Table 1). The structures of the complexes were
determined by molecular replacement using the previously
determined structure of apo-BoNT/DC-HC (Protein Data Bank
[PDB] code: 3N7L) as a search model (Karalewitz et al., 2010).
The asymmetric unit contains, in both cases, three molecules
that were all similar (rmsd of 0.5 A˚2 in between the molecules).
Chain b displayed limited differences in the distal part of the pro-
tein, with differences in the loops 923–930 and 1030–1037, likely
induced by the crystal packing. However, this face of the protein
does not interact with any ligand, and the differences can thus be
neglected. The electron density accounted formost of the BoNT/
DC-HC sequence, with all residues between 863 and 1263
visible, with the exception of a flexible loop between residues
1052 and 1059 (Figure 1A). For both structures, well-defined
electron density, not part of BoNT/DC-HC protein, appeared
directly after molecular replacement, and became even clearer11, September 3, 2013 ª2013 Elsevier Ltd All rights reserved 1603
Figure 1. Structure of the BoNT/DC-HC , Syt
Complex
(A) Cartoon representation of the overall structure of
BoNT/DC-HC bound with the Syt-II peptide con-
taining the toxin binding site. The bound Syt-II pep-
tide (orange) forms an a helix and docks to the
C-terminal region of BoNT/DC-HCC. The residues
involved in the GBS andGBL are shown in green and
red, respectively.
(B and C) Enlargement of the Syt-II (B) and of the
Syt-I (C) binding sites. Electron density for Syt is
shown in light bluemesh (SigmaA-weighted 2FO – FC
map, contoured at 1 s), with the modeled Syt-II and
Syt-I (orange and teal, respectively). The start and
end of each peptide is marked in the figure. The re-
maining residues of Syt-II and Syt-I are disordered
and are not visible in the structure.
Structure
BoNT/DC in Complex with Syt-I and Syt-IIafter refinement. This density was unambiguously assigned
to the Syt-I and Syt-II recognition domains, respectively (Figures
1B and 1C).With the exception of three residues on both ends for
Syt-I, and 2 and 3 on the N- and C-terminal ends for Syt-II, the
entire peptide was visible in the electron density. The bound re-
gions correspond to residues 36–50 in Syt-I and 42–57 in Syt-II.
The overall structure of BoNT/DC-HC bound to Syt-I, or Syt-II,
is similar to the previously reported apo structure of BoNT/DC-
HC (Karalewitz et al., 2010), with an rmsd of 0.8 A˚. Binding of
Syt does not induce any significant structural changes in
BoNT/DC, instead the binding pocket is preset for binding of
both Syt-I and Syt-II. The luminal domain of Syt-II, which con-
tains the toxin binding site, has previously been shown to be
disordered in solution (Jin et al., 2006). Upon binding to BoNT/
DC, residues 37–48 in Syt-I, and 43–54 in Syt-II, form an amphi-
pathic helix, with the rest of the ordered residues in an extended
conformation (Figures 1B and 1C). The Syt-I and Syt-II molecules
are positioned virtually identical within the binding site (Figures
2A and 2B). Syt-I and Syt-II are both bound in a defined register,
verifying that they have one defined binding mode. The BoNT/
DC , Syt-I complex reported here confirms at the structural level
that Syt-I and -II are recognized by the same receptor binding
pockets in a highly similar way. This is very likely the case also
for Syt-I and Syt-II binding to BoNT/B and BoNT/G.
BoNT/DC Interactions with Syt
The hydrophobic side of the Syt amphipathic helix docks into a
hydrophobic patch at the C-terminal region of BoNT/DC-HCC
(Figures 2A–2C). The interface between BoNT/DC and Syt buries1604 Structure 21, 1602–1611, September 3, 2013 ª2013 Elsevier Ltd All rights reserveda solvent-accessible surface area of 652
and 668 A˚2 for Syt-I and Syt-II, respectively,
slightly larger than the 608 A˚2 that gets
buried on BoNT/B upon Syt-II binding
(Chai et al., 2006). The contacts are mainly
constituted by hydrophobic and van der
Waals interactions, with residues M1179,
V1191, L1196, L1226, L1235, and I1264
forming the hydrophobic patch where Syt
binds (Figures 2A–2C). Y1180 and K1181,
despite being overall hydrophilic, also pro-
vide hydrophobic contacts, both to F54 onSyt-II (F47 in Syt-I). A total of four hydrogen bonds are formed
to Syt, with three hydrogen bonds formed to N56 on Syt-II
(N49 in Syt-I), two coming from N1185 and one from the back-
bone of P1182. The last hydrogen bond is formed between the
backbone of R1234 and Q43 on Syt-II (K36 in Syt-I). Finally
one salt bridge is also formed between E57 of Syt-II (E50 in
Syt-I) and K1181 of BoNT/DC. There are only three differences
between human Syt-I and rat Syt-II that are involved in the toxin
binding, namely, Q43, M46, and F55, in Syt-II being exchanged
to lysine, alanine, and methionine in Syt-I, respectively
(Figure 2D).
To further characterize the binding, we mutated six residues
located along the binding interface at the surface of BoNT/DC
(M1179, P1182, N1185, V1191, L1235, I1264) (Figures 2A and
2B), replacing them with serine to abolish the hydrophobic inter-
actions that cover the entire binding site (Figure 2C). No major
structural changes were induced by the mutations, as verified
by circular dichroism (CD) experiments (Figure S1A available on-
line). These mutants were purified as glutathione S-transferase
(GST)-tagged recombinant proteins and immobilized on beads
and were used to pull down native Syt-I and -II from rat brain
detergent extracts. As shown in Figure 2E, mutating residues
in the center of the binding interface, M1179, V1191, and
I1264, abolished binding of both Syt-I and –II. Mutating a residue
at the periphery of the binding interface (L1235) decreased the
binding significantly (3-fold). A similar decrease is seen in the
P1182S mutant, which does not remove the H-bond. In this
case, it is likely due to changes in the loop region, also containing
N1185, which causes the decrease in binding. Mutating N1185
Figure 2. Interactions between BoNT/DC
and Syt-I/II
(A) A close-up view of the binding interface
between BoNT/DC (gray) and Syt-II (orange).
All directly interacting residues are shown as
sticks. Violet residues at the Syt binding site were
selected for mutagenesis studies as described
in (E).
(B) Close-up view of the binding interface between
BoNT/DC and Syt-I (teal), with the same coloring as
in (A). E45, marked with a red star, is the only res-
idue that is different between human and rat Syt-I.
E45 is, as seen here, not involved in the binding to
the toxin.
(C) Surface representation of the Syt-II binding site
of BoNT/DC (gray), with bound Syt II (orange) and
the hydrophobic residues of BoNT/DC that form the
Syt-II binding site shown in green.
(D) Comparison of Syt-I and Syt-II bound to BoNT/
DC, as seen when superimposing only the BoNT/
DC protein chains upon each other. The hydro-
phobic face of the amphipathic Syt helices, as
seen from the BoNT/DC binding site, with the
three differences in the binding region between
Syt-I and Syt-II highlighted. The other differences
between the two isoforms are located in the hy-
drophilic face of the helix that facing away from the
binding site and are not involved in the binding to
BoNT/DC.
(E) Upper panel: mutated BoNT/DC-HC were
used to pull down native Syt-I/II from rat brain
detergent (Triton X-100) extracts. Wild-type (WT)
BoNT/DC-HC and GST protein were assayed in
parallel as controls. Bound Syt-I/II were detected
via immunoblot using their specific antibodies.
GST-tagged BoNT/DC-HCs used in pull-down
assays were visualized by Coomassie blue staining
to indicate equal loading. Lower panel: binding of
Syt-I/II to BoNT/DC-HC mutants was quantified
and normalized to the amount of binding to WT
BoNT/DC-HC. The error bars represent the SEM. See also Figure S2 for a sequence alignment of Syt isoforms. See also Figure S1 for (1) CD spectra illustrating
that the mutations in BoNT/DC-HC does not induce any major structural changes and (2) for a schematic overview of the two binding sites.
Structure
BoNT/DC in Complex with Syt-I and Syt-IIto a serine, thereby removing two hydrogen bonds to Syt, hardly
disturbed the binding, as it retained 88% and 68% of the binding
to Syt-I and Syt-II, respectively. The results for the site-directed
mutagenesis are similar between the binding of both Syt-I and
Syt-II for all mutants, consistent with the high similarity between
the Syt-I and Syt-II complexes reported here. These results are
consistent with our structural data and further show that the
hydrophobic interactions are an important force in Syt binding
to BoNT/DC. Human and rat Syt-I differs only in one residue
(E45Q) that is facing away from the toxin and can thus be consid-
ered virtually identical with respect to toxin binding (Figure 2B).
We previously demonstrated that human Syt-II did not
have detectable binding to BoNT/DC in pull-down assays
(Peng et al., 2012). This is due to a single residue change at
position F54 of Syt-II (rat sequence number); the F residue is
highly conserved across a majority of vertebrates, but changes
to L in humans (Figure S2). The crystal structure of the BoNT/
DC , Syt-II complexes now provided a structural explanation:
F54 is located at the core of the binding interface and forms mul-
tiple hydrophobic interactionswith residues in BoNT/DC (Figures
2A and S1B). The F54Lmutation leads to the loss of ap-stackingStructure 21, 1602–16interaction with Y1206, as well as a (minor) hydrophobic
mismatch when the smaller leucine residue cannot cover the
entire hydrophobic patch previously covered by F54. Therefore,
the high-affinity receptor for BoNT/DC in humans is restricted to
Syt-I. This makes the binding domain of BoNT/DC a potential
tool to specifically target human neurons expressing Syt-I.
Furthermore, the protein receptor and ganglioside coreceptor
binding sites could be altered to modify the affinity and speci-
ficity of the BoNT/DC binding domain.
BoNT/DC Has a Different Syt Binding Site Compared to
BoNT/B
We next compared the structure of BoNT/DC , Syt-II versus
BoNT/B , Syt-II (Chai et al., 2006; Jin et al., 2006). As shown in
Figure 3A, the overall structure of BoNT/B-HC and BoNT/DC-
HC are fairly similar, with an rmsd of 2.3 A˚. However, there are
large differences in surface regions of the proteins. Syt-II does
not bind at the same site as in BoNT/B, but instead binds in a
distinct binding pocket in BoNT/DC located on another face of
the HCC domain. Furthermore the binding is shifted 90 to the
Syt-II binding site in BoNT/B (Figure 3A). Furthermore, the region11, September 3, 2013 ª2013 Elsevier Ltd All rights reserved 1605
Figure 3. BoNT/DC Utilizes a Different Syt-II
Binding Site Compared to BoNT/B
(A) The structure comparison between BoNT/DC
(gray) , Syt-II (orange) complex and BoNT/B
(green) , Syt-II (yellow). The right panel is an
enlarged view of the Syt-II binding sites in BoNT/DC
(gray) and BoNT/B (green), with Syt-II peptide
bound to BoNT/DC labeled in orange and Syt-II
peptide bound to BoNT/B labeled in yellow. The N-
and C-terminal residues of the toxin binding site in
Syt-II are marked. The Syt-II binding sites in BoNT/
DC and BoNT/B are rotated approximately 90 from
each other. The C-terminal ends of Syt-II (E57 in
BoNT/DC , Syt-II and K60 in BoNT/B , Syt-II) are in
close vicinity of each other.
(B) Schematic overview of the interactions between
BoNT/DC and BoNT/B to Syt-II. Solid lines repre-
sent hydrophobic contacts, dotted black lines
represent hydrogen bonds, and red dashed lines
represent salt bridges. Syt-II residues are color
coded: cyan indicates binding to BoNT/DC only,
green indicates binding to BoNT/B only, and red
indicates residues contribute to binding of both
BoNT/DC and B.
See also Figure S2 for a sequence comparison
between Syt isoforms from different species.
Structure
BoNT/DC in Complex with Syt-I and Syt-IIof Syt-II bound to each toxin is shifted. BoNT/DC binding in-
volves residues 43–57, whereas BoNT/B binding involves resi-
dues 44–60 of Syt-II (Figure 3A, enlarged panel). It is interesting
to note that the C-terminal end of Syt-II (E57 of Syt-II in BoNT/DC
and K60 of Syt-II in BoNT/B) ends up at a similar position in both
toxins, despite the perpendicular orientation of the two Syt-II
binding sites (Figure 3A, right panel). This would put both toxins
at similar position to the membrane, as the C-terminal of Syt-II
recognition sequence directly precedes its transmembrane
domain. In addition, BoNT/DC might have slightly higher flexi-
bility than BoNT/B, as there are three extra residues between
the bound region of Syt-II and its anchoring transmembrane helix
in BoNT/DC.
The structural comparison also revealed that both BoNT/DC
and BoNT/B recognize Syt-II in a similar manner (Figures 3B,
S1B, and S1C). The hydrophobic interactions play the key role,
with the core residues F47, L50, F54, and F55 in Syt-II forming
the hydrophobic contacts to both toxins (Figure 3B, black line).
In addition, the residue E57 also forms a salt bridge with different
lysine residues in both toxins (Figure 3B, red dashed line). The in-
teractions to Syt-II are further strengthened by similar numbers
of hydrogen bonds, four in BoNT/DC and three in BoNT/B (Fig-
ure 3B, black dashed line). On the other hand, the toxin residues
forming the binding site are not conserved and are located at a
different area of the protein (Figure 3). For instance, F47 from
Syt-II stacks with Y1181 and F1194 in BoNT/B, whereas the
same residue does not have any p interactions in BoNT/DC,
only hydrophobic interactions with L1235 and E1265.1606 Structure 21, 1602–1611, September 3, 2013 ª2013 Elsevier Ltd All rights reservedComparison of BoNT/DC to BoNT/C
Among the seven BoNTs, the receptor
binding domain of BoNT/DC has the high-
est sequence identity with BoNT/C, 92% in
the HCN and 61% in the HCC domains(Peng et al., 2012). However, BoNT/C does not use Syt-I/II as
receptors. To understand the molecular basis for this diver-
gence, we compared the structure of BoNT/DC , Syt-II with
BoNT/C-HC in complex with sialic acids (PDB code: 3R4S).
Overall, the structures of the two toxins are highly similar, with
an rmsd of mere 0.9 A˚, but we found that BoNT/C lacks a hydro-
phobic patch in the BoNT/DC Syt binding region, leading to an
incompatible Syt binding site (Figures 4A and S3).
As mentioned earlier, no protein receptor has been identified
for BoNT/C; rather, it has been proposed that BoNT/C has at
least two different ganglioside binding sites (Karalewitz et al.,
2012; Strotmeier et al., 2011), involving three regions: (1) the
GBS found in other BoNTs, (2) the GBL, and (3) a sialic acid bind-
ing pocket (Sia-1, Figure 4B). The GBL and the sialic acid binding
pocket could be part of one ganglioside interaction area, as com-
plex gangliosides can reach both simultaneously (Figure 5). The
ability to bind multiple gangliosides may allow BoNT/C to bind
neurons without protein receptors. As BoNT/DC shares high
sequence identity to BoNT/C in their receptor binding domain,
are all these ganglioside binding sites conserved in BoNT/DC?
Previous biochemical characterization and crystal structure of
BoNT/DC have demonstrated that the GBS is conserved and
located in a similar position as in BoNT/A (Nuemket et al.,
2011). The GBL is also conserved between BoNT/C and DC
(Karalewitz et al., 2010; Nuemket et al., 2011). Mutations in
both the GBS and GBL of BoNT/DC abolished its binding to pu-
rified gangliosides and to cell surfaces (Nuemket et al., 2011),
demonstrating their role for binding gangliosides.
Figure 4. BoNT/DC Comparison with BoNT/C
(A) Surface representation of BoNT/DC (left panel)
and BoNT/C (right panel), with hydrophilic surface in
blue and hydrophobic in green. The Syt-II recogni-
tion sequence bound to BoNT/DC is shown in both
figures. It is clear that Syt-II cannot bind to BoNT/C,
due to a lack of the important hydrophobic patch
found in BoNT/DC, as well as steric clashes.
(B) Superimposing BoNT/C-HC (cyan) , sialic acid
complex with BoNT/DC-HC (gray) , Syt-II (orange)
complex. The ganglioside GT1b (green) was also
modeled onto established ganglioside binding site
(GBS) based on the previously determined BoNT/A-
GT1b structure (PDB code: 2VU9). The biologically
relevant sialic acid moiety, cocrystallized together
with BoNT/C, is shown in blue. The ganglioside
binding loop (GBL) is shown in red.
(C) Close-up view of the Sia-1 sites in BoNT/C (cyan)
and BoNT/DC (gray). Conserved residues in BoNT/
DC are marked in the figure, and possible hydrogen
bonds between the sialic acid and BoNT/DC are
shown as dashed lines. The Sia-1 site is highly
conserved between BoNT/C and BoNT/DC.
See also Figure S3 for a structure-based sequence
alignment of BoNT/DC-HC and BoNT/C-HC.
Structure
BoNT/DC in Complex with Syt-I and Syt-IIWe compared the Sia-1 site of BoNT/DC with BoNT/C (Strot-
meier et al., 2011); this shows that the Sia-1 site from BoNT/C is
largely intact in BoNT/DC, with most of the important residues
and contacts conserved (Figures 4C and S3). Most hydrogen
bonds are conserved in this region, with residues Y1142,
I1170, D1171, and Y1175 (numbering from BoNT/DC) forming
the conserved core (Figure 4C). Furthermore, the backbone of
K1123 and G1124 is in a similar position as their corresponding
residues in BoNT/C and can form hydrogen bonds to the sialic
acid. D1171 is conserved in BoNT/DC, and although it cannot
form a hydrogen bond directly to the Sia-1 molecule, a bridging
water molecule could form the bridge, similar to what has been
observed in the BoNT/C , sialic acid complex structure (Strot-
meier et al., 2011). For BoNT/DC to form the Sia-1 site, the
side chain of K1122 would have to change its conformation.
That, together with a small change in the backbone of Gly1124
and Asn1125, situated in a flexible loop, would form a virtually
identical sialic acid binding site as in BoNT/C.
DISCUSSION
It is puzzling how BoNT/DC, which has a rather low sequence
identity to BoNT/B and does not have the well-established Syt
binding site found in BoNT/B, could recognize the same toxin
binding site on Syt-II as BoNT/B. Here, we solved the cocrystal
structures of BoNT/DC-HC bound to either the Syt-I or Syt-II
peptide containing the toxin binding domain. The structures re-
vealed that BoNT/DC possesses a distinct Syt binding siteStructure 21, 1602–1611, September 3, 2013located adjacent, but rotated approxi-
mately 90, to the Syt-II binding site in
BoNT/B. Structure-based mutagenesis
studies further confirmed the location of
the Syt binding site. Although the Syt bind-
ing sites in BoNT/DC and BoNT/B are notconserved and located at different positions, they both have a
large hydrophobic patch that allows binding of the hydrophobic
side of the Syt amphipathic helix. The interactions to Syt-II, in
both proteins, are mainly mediated by hydrophobic forces,
with an additional three to four hydrogen bonds and one salt
bridge. The key residues of Syt-II involved in the binding, such
as F47, F54, and F55, are utilized by both BoNT/DC and
BoNT/B. This provides a structural explanation for the previous
finding that mutations at these residues in Syt-II reduce binding
of both BoNT/DC and BoNT/B to Syt-II (Peng et al., 2012).
The fact that the BoNT toxin family has developed two non-
conserved binding domains to recognize the same stretch of
Syt suggests an intriguing possibility of convergent evolution,
where BoNT/DC and BoNT/B have taken two different routes
to end up binding very similar regions of Syt. The short stretch
of the toxin binding site (<20 residues) in both Syt-I and Syt-II
certainly possesses attractive properties for mediating protein-
protein interactions. This region is unstructured in solution but
can form an amphipathic helix and bind to hydrophobic binding
sites of toxins (Chai et al., 2006; Jin et al., 2006; Peng et al.,
2012). In both isoforms, it is located adjacent to the transmem-
brane domain of Syt, therefore providing a way to anchor toxins
within the proximity of the membrane. In fact, the C terminus of
the toxin binding site in Syt-II, which precedes the transmem-
brane domain, is at approximately the same position in both
the BoNT/DC and BoNT/B complexes. This is very likely the
case also for Syt-I; however, no structure is available of BoNT/
B bound to Syt-I. Both BoNT/DC and BoNT/B are anchored atª2013 Elsevier Ltd All rights reserved 1607
Figure 5. A Model of BoNT/DC Binding to Its Neuronal Receptors
BoNT/DC-HC (gray) and the Syt-II peptide (orange) come from data presented
here. The ganglioside binding loop (GBL) is shown in red. The rest of the BoNT
structure, HN (purple) and light chain (pink), is modeled onto the DC structure
using the previously determined BoNT/B structure (PDB code: 2NP0). The
ganglioside (green) is modeled based on the BoNT/A-GT1b structure (PDB
code: 2VU9), and the potential second ganglioside (blue) is superimposed to
the sialic acid moiety in the Sia-1 site of BoNT/C (PDB code: 3R4S). The
transmembrane section of Syt-II is shown as a yellow box.
Structure
BoNT/DC in Complex with Syt-I and Syt-IIsimilar distance to membranes. This convergence may reflect a
spatial constraint in order to maintain simultaneous ganglioside
binding and/or to facilitate the later translocation step.
The toxin binding site in Syt-II is also highly conserved across
vertebrates (Craxton, 2010), although whether it has any physio-
logical function remains to be determined. Interestingly, seem-
inglyminor residue changeswithin this region in different species
have significant impact on binding of BoNTs. For instance, a sin-
gle residue change of F54 (in rat/mouse sequence) to a leucine
(as in human Syt-II) dramatically reduces binding of BoNT/B,
G, and DC (Peng et al., 2012; Strotmeier et al., 2012).
The receptor binding domain of BoNT/DC has the highest
sequence identity to BoNT/C among the seven BoNTs, yet the
Syt binding site in BoNT/DC is not conserved in BoNT/C. Indeed,
it has been proposed that BoNT/C does not use a protein recep-
tor but utilizes at least two gangliosides, with the GBS and GBL
as well as a Sia-1 site involved in ganglioside binding (Karalewitz
et al., 2012; Strotmeier et al., 2011). Structural comparison
between the BoNT/DC , Syt complexes and the BoNT/C , sialic
acid complex revealed that the Sia-1 site is mostly conserved in
BoNT/DC (Strotmeier et al., 2011). Because both the GBS and
the GBL are also conserved in BoNT/DC and their involvement
for ganglioside binding has been further confirmed via mutagen-
esis studies (Nuemket et al., 2011), BoNT/DC could have two1608 Structure 21, 1602–1611, September 3, 2013 ª2013 Elsevier Ltganglioside binding sites, like BoNT/C (Karalewitz et al., 2012;
Strotmeier et al., 2011). The Syt binding site of BoNT/DC is inde-
pendent of both the GBS and the GBL/Sia-1 site; therefore,
BoNT/DC has the potential to bind at three anchoring points
on the neuronal membrane (Figures 4B and 5). These three sites
give us sterical restrictions, allowing us to model the entire com-
plex on the membrane via a triple binding site model (Figure 5). It
is currently not clear whether the GBL binds gangliosides inde-
pendently, or whether it acts in a dependent manner with the
Sia-1 site or GBS (Nuemket et al., 2011; Strotmeier et al.,
2011). The GBL is, however, close in space to where a potential
complex ganglioside would be if bound to the Sia-1 site (Fig-
ure 5). With the Sia-1 binding the sialic acid moiety of a ganglio-
side, as previously suggested for BoNT/C (Karalewitz et al.,
2012; Strotmeier et al., 2011), a second GBS could then be
formed consisting of the Sia-1 site and the GBL together, a
GBL/Sia-1 site. The tryptophan of the GBLwould be in a suitable
location to interact and stackwith a sugarmoiety further down an
oligosaccharide bound at the Sia-1 site (Figure 5). Furthermore,
the exposed hydrophobic residues of the GBL are well posi-
tioned for a direct interaction with the membrane, as seen in Fig-
ure 5. The exposed nature of the GBL is interesting also from a
pharmacological perspective. As previously noted, it could be
a potential site for targeting serotype specific antibodies (Kroken
et al., 2011a). One biological reason for two ganglioside binding
sites could be the possibility to compensate for the lower affinity
BoNT/DC has toward Syt-I/II compared to BoNT/B (Peng et al.,
2012). By having three independent binding sites BoNT/DC in-
creases its binding affinity to the neuronal membrane. The re-
ceptor binding sites are well aligned for simultaneous interaction
with the membrane and could be suitable targets for antitoxins,
perhaps utilizing the possibility to block several sites simulta-
neously. Although the mechanism of ganglioside binding of
BoNT/DC requires further experimental validation, the structure
presented here suggests that BoNT/DC binds to three sites on
the membrane, an extension of the original ‘‘double-receptor’’
model (Montecucco, 1986).Conclusions
The structures presented here reveal that BoNT/DC recognizes
Syt via a different binding region than BoNT/B. The Syt binding
sites in BoNT/B and BoNT/DC are formed by distinct residues.
The nonconserved nature of these two Syt binding sites and their
distinct locations suggest that they likely evolved independently
to recognize the same recognition domain of Syt. The binding of
Syt-I and Syt-II to BoNT/DC is highly similar and does not induce
any structural changes in the toxin. Mutational studies highlight
the key hydrophobic interactions in Syt binding. The structures
reveal that the ganglioside binding sites in BoNT/DC are inde-
pendent of the Syt binding site. Therefore, the structures
reported here suggest that BoNT/DC may bind both a protein
receptor and two separate gangliosides.EXPERIMENTAL PROCEDURES
Constructs, Peptides, and Antibodies
The cDNAs encoding BoNT/DC-HC (residues 859–1285, GenBank:
AB461915.1) was synthesized by GenScript with codon optimized for E. coli
expression and was subcloned into pET28a vector using NheI/XhoI sites ford All rights reserved
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BoNT/DC in Complex with Syt-I and Syt-IIexpression as recombinant proteins with a His6 tag fused to the N terminus.
BoNT/DC-HC was also subcloned into pGEX-4T vector for expression as
GST-tagged recombinant proteins, which was used for pull-down assays.
Mutagenesis of BoNT/DC-HC was carried out using Quickchange site-
directed mutagenesis kit following manufacturer’s instructions (Agilent Tech-
nologies). Peptides corresponding to the toxin binding site in rat Syt-II
(residues 40–60) and human Syt-I (residues 33–53) were synthesized (>95%
purity) by JPT Peptide Technologies. Mouse monoclonal antibodies for Syt-I
(Cl41.1) was generously provided by E. Chapman. Mouse monoclonal anti-
Syt II was purchased from BD Transduction.
Protein Expression and Purification
His6-tagged BoNT/DC-HC was expressed in E. coli (BL21 strain). The cells
were grown in EPCM1 medium containing 50 mg/ml kanamycin and grown in
a 7 l fermentor (Applikon Biotechnology) at 37C (pH 7.0) with mixing and addi-
tion of air and oxygen to maintain an excess of oxygen. The temperature was
lowered to 20C at an OD600 of 5–7. Upon reaching the set temperature, the
expression was induced upon the addition of isopropyl b-D-1-thiogalactopyr-
anoside (IPTG) with a final concentration of 0.8mM. GST-tagged BoNT/DC-HC
was also expressed in E. coli (BL21) and grown in lysogeny broth containing
50 mg/ml carbenicillin. The cells were grown at 37C until an OD600 of 0.5,
whereupon the temperature was lowered to 18C and expression was induced
with 0.25 mM IPTG. After overnight induction, the cells were harvested, and
the pelleted cells were frozen in 80C. For His6-tagged BoNT/DC-HC purifi-
cation, pellets were thawed and resuspended in 20 mM phosphate buffer
(pH 7.4), 500 mM NaCl, and 20 mM imidazole (lysis buffer) and sonicated at
95% amplitude on ice for three rounds of 3 3 10 s with 5 s rest between
each 10 s sonication. Cell debris was removed by centrifugation at 23,000 3
g for 20 min at 4C. The soluble fraction was loaded to a HisTrap HP Ni column
(GE Healthcare). The column was subsequently washed for five column vol-
umes (CVs) with lysis buffer. Contaminating proteins were washed away
with five CVs of lysis buffer containing 90 mM imidazole. Elution was per-
formed with lysis buffer containing 250 mM imidazole. The purified protein
was subsequently dialyzed against 20 mM HEPES (pH 7.5), 150 mM NaCl,
10% (v/v) glycerol, and 1mMDTT and subsequently flash frozen in liquid nitro-
gen and stored at80C. For binding and circular dichroism analysis, WT and
mutant BoNT/DC-HC were purified as GST-tagged recombinant proteins. The
samples were analyzed by SDS-PAGE.
Brain Detergent Extracts, GST Pull-Down Assay, and Immunoblot
Analysis
Rat brain detergent extracts were prepared as previously described (Peng
et al., 2011). Ten micrograms of GST-BoNT/DC-HC or GST was immobilized
on glutathione-Sepharose beads (GE Bioscience) and were subsequently
incubated with 0.5 ml rat brain detergent extracts for 1 hr at 4C. Beads
were washed three times using Tris buffer (20 mM Tris, 150 mM NaCl
[pH 7.4]) plus 0.5% Triton X-100. Ten percent of bound materials were sub-
jected to SDS-PAGE, followed by either immunoblot analysis using the
enhanced chemiluminescencemethod (Pierce) to detect Syt-I/II or Coomassie
blue staining to visualize GST-BoNT/DC-HCs. The study was carried out in
strict accordance with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health. The protocol
was approved by the Standing Committee on Animals of Harvard Medical
School. All efforts were made to minimize suffering of animals.
Circular Dichroism Experiments
CD measurements were done on a Chirascan circular dichroism spectrometer
(Applied Photophysics). Four hundred microliters of protein sample at a protein
concentrationof0.04mg/ml in50mMKPi (pH7.5)wasused incuvettewith2mm
path length. The protein concentration was based on the calculated extinction
coefficient for the GST-tagged BoNT/DC-HC (127,340 M
1cm1), on samples
that were concentrated to 1 mg/ml and subsequently diluted to 0.04 mg/ml
for the CD measurement. Samples were measured between 194 and 260 nm
at 20C. Measurements were done in quadruplets and subsequently averaged.
Crystallization and Structure Determination
BoNT/DC-HC was thawed, and human Syt-I or rat Syt-II peptide was added to
a final concentration of 0.8 mM and was crystallized using the vapor diffusionStructure 21, 1602–16technique. The crystals were grown from a solution containing 1.8–2.2 M
NaSO4 and 0.1 M Na-cacodylate (pH 7.0) at 18
C. Crystals appeared within
5 days and grew to full size after 2–4 weeks. They were cryoprotected with
mother liquor supplemented with 18% glycerol.
Diffraction data of the BoNT/DC , Syt-II complex were collected at 0.95 A˚ at
beamline 14.1, BESSY, and for the BoNT/DC , Syt-I complex on the PX1
beamline at the Swiss Light Source, Paul Scherrer Institute, Villigen,
Switzerland. Data processing and reduction were carried out using XDS
(Kabsch, 2010) and programs from the CCP4 suite (Collaborative Computa-
tional Project 4, 1994). Relevant statistics for data processing and refinement
are shown in Table 1. The phase problem was solved using molecular replace-
ment, using an apo structure of BoNT/DC-HC (PDB code: 3N7L). A few cycles
of refinement in Refmac5 (Murshudov et al., 1997) using translation libration
screw (TLS) refinement (Winn et al., 2001), interspersed with manual model
building using Coot (Emsley and Cowtan, 2004), were necessary to complete
the full model. The final model contains residues 863–1284, with the exception
of residues 1052–1059 that reside in a loop region and are presumed to be
disordered. With the exception of two to three residues on both termini, the
entire peptide was visible in the electron density, corresponding to residues
36–50 in human Syt-I and to 42–57 in rat Syt-II.
ACCESSION NUMBERS
The coordinates and structure factors of the BoNT/DC complexes with human
Syt-I and rat Syt-II were deposited in the PDB with the accession codes 4ISQ
and 4ISR, respectively.
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